Novogen Limited (ADR) (NASDAQ:NVGN)

CAPS Rating: 1 out of 5

The Company is a pharmaceutical company involved in the discovery, development, manufacture and marketing of products based on the emerging field of phenolic technology.

Results 1 - 12 of 12

Recs

0
Member Avatar pchop12316 (61.58) Submitted: 3/18/2015 4:05:22 PM : Underperform Start Price: $4.05 NVGN Score: -7.85

not likely to hold today's gains

Recs

1
Member Avatar zzlangerhans (99.81) Submitted: 3/18/2015 10:21:04 AM : Underperform Start Price: $4.19 NVGN Score: -2.96

The day wouldn't be complete without a visit to Novogen's website to see what nonsensical press release is causing the share price to spike, a spike whose gap will fill in days if not hours. Looks like this time it's more unpublished benchtop labwork that they're trying to get everyone excited about. I'd be a lot more excited if Novogen shares were available to short on days like this, but they never show up until the gap is almost completely filled.

Recs

0
Member Avatar seymourfroggs (< 20) Submitted: 1/17/2015 1:53:16 AM : Outperform Start Price: $2.30 NVGN Score: +84.97

Small lean group, all scientists, but with clear idea about not letting go of their property; hanging on to 51% come H or HW.
Two paths, but focusing on one of these. A molecule which is both a rather fundamental and quite selective "poison". It is the only thing I know of that will kill cancer stem cells, so making cancer recurrence less likely. It works on several cancer types.
Its soon to start being trialed in a safety study.
I like the expertise, the cautious enthusiasm, and what look like two superb molecules.

Recs

0
Member Avatar TMFFlygal (99.34) Submitted: 1/16/2015 8:12:55 PM : Underperform Start Price: $2.30 NVGN Score: -84.97

Junk

Recs

1
Member Avatar palmeiras (43.88) Submitted: 11/5/2013 12:52:50 AM : Outperform Start Price: $6.18 NVGN Score: -47.62

CS-6 drug shows high potency. Potential partnership announced in letter to shareholders CEO trialed an earlier version of the drug and sent his cancer into remission (that's faith in your product!)

Recs

1
Member Avatar deuspecuniae (97.04) Submitted: 5/1/2008 12:11:16 PM : Outperform Start Price: $190.15 NVGN Score: -151.09

The looming recession that bernanke and the whole federal reserve gang have set this country towards will send alot of investors into the pharmaceutical's sector--being the traditional recessionary savior to say the least. Plus, most pharmaceutical stocks have been beaten down this past winter, and I see a reversal across the entire sector. Also, those companies already on a run will continue due to the upward momentum this summer from key reversals and upgrades throughout the sector.

Recs

0
Member Avatar skytalon1 (< 20) Submitted: 4/22/2008 8:51:37 PM : Outperform Start Price: $207.00 NVGN Score: -153.33

i HAVE NOT DONNE ANY HOMEWORK ON THIS ONE BUT HAVE A GOOD FEELING IT WILL GET HOT IN TIME

Recs

0
Member Avatar Biotech2008 (70.27) Submitted: 1/4/2008 9:58:21 PM : Outperform Start Price: $134.15 NVGN Score: -148.50

applefoot @5.53

Recs

0
Member Avatar tharlow (83.01) Submitted: 11/9/2007 12:04:31 AM : Outperform Start Price: $190.00 NVGN Score: -146.19

Ready to explode.

Recs

0
Member Avatar COOLJOB (< 20) Submitted: 9/23/2007 7:44:43 PM : Outperform Start Price: $200.00 NVGN Score: -139.75

Wish to keep it to myself

Recs

0
Member Avatar Kywong (< 20) Submitted: 6/14/2007 2:35:48 AM : Outperform Start Price: $217.50 NVGN Score: -141.54

The base technology upon which Novogen is basing its work shows plenty of promise as an enabler. I suspect that being a 'toolmaker' for drug developers is a safer proposition than being an out and out drug developer.

Recs

0
Member Avatar LALetal (< 20) Submitted: 2/28/2007 1:09:57 PM : Outperform Start Price: $272.25 NVGN Score: -153.50

Flying under the radar with potenial

Results 1 - 12 of 12

Featured Broker Partners


Advertisement